Literature DB >> 1452640

Evidence of presymptomatic cognitive decline in Huntington's disease.

R Diamond1, R F White, R H Myers, C Mastromauro, W J Koroshetz, N Butters, D M Rothstein, M B Moss, J Vasterling.   

Abstract

Asymptomatic persons at risk for Huntington's disease (HD) (N = 28) were assessed with neuropsychological, psychiatric, and neurologic tests while undergoing genetic linkage studies to determine their probability of carrying the HD gene. Those participants who were subsequently identified as probable gene carriers did not differ on neurologic or psychiatric examination from those subsequently identified as probable noncarriers. Neuropsychological data are presented for a subset of participants free of other conditions (such as alcoholism) putting them at risk for cognitive deficits. Among these subjects, probable gene carriers were inferior to probable noncarriers on the neuropsychological battery as a whole and on several individual tests involving learning and memory. The results suggest the presence of cognitive decline prior to identifiable motor impairments in HD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452640     DOI: 10.1080/01688639208402547

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  19 in total

1.  Intelligence indices in people with a high/low risk for developing Huntington's disease.

Authors:  G M de Boo; A Tibben; J B Lanser; A Jennekens-Schinkel; J Hermans; M Vegter-van der Vlis; R A Roos
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

2.  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.

Authors:  V Pedersen; W J Schmidt
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation.

Authors:  J R Campodonico; A M Codori; J Brandt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

4.  Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers.

Authors:  V Hahn-Barma; B Deweer; A Dürr; C Dodé; J Feingold; B Pillon; Y Agid; A Brice; B Dubois
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

5.  Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease.

Authors:  S Palfi; R J Ferrante; E Brouillet; M F Beal; R Dolan; M C Guyot; M Peschanski; P Hantraye
Journal:  J Neurosci       Date:  1996-05-01       Impact factor: 6.167

6.  Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease.

Authors:  L Blackmore; S A Simpson; J R Crawford
Journal:  J Med Genet       Date:  1995-05       Impact factor: 6.318

7.  Verbal episodic memory declines prior to diagnosis in Huntington's disease.

Authors:  Andrea C Solomon; Julie C Stout; Shannon A Johnson; Douglas R Langbehn; Elizabeth H Aylward; Jason Brandt; Christopher A Ross; Leigh Beglinger; Michael R Hayden; Karl Kieburtz; Elise Kayson; Elaine Julian-Baros; Kevin Duff; Mark Guttman; Martha Nance; David Oakes; Ira Shoulson; Elizabeth Penziner; Jane S Paulsen
Journal:  Neuropsychologia       Date:  2007-01-09       Impact factor: 3.139

8.  Abnormal error-related antisaccade activation in premanifest and early manifest Huntington disease.

Authors:  Jason Rupp; Mario Dzemidzic; Tanya Blekher; Veronique Bragulat; John West; Jacqueline Jackson; Siu Hui; Joanne Wojcieszek; Andrew J Saykin; David Kareken; Tatiana Foroud
Journal:  Neuropsychology       Date:  2011-05       Impact factor: 3.295

9.  Neuropsychological characteristics of Huntington's disease carriers: a double blind study.

Authors:  N K Rosenberg; S A Sørensen; A L Christensen
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

10.  Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.

Authors:  Jurgen Lemiere; Marleen Decruyenaere; Gery Evers-Kiebooms; Erik Vandenbussche; Rene Dom
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.